Summary.-This report compares the results at 36 months for 121 patients treated with radiotherapy alone (R) and 115 with radiotherapy followed by 3-drug chemotherapy (RC) for small-cell carcinoma of the lung of "limited" extent.
The RC patients had an increased survival (P=0.009 by log-rank test). The median survival was 25 weeks for the R patients and 43 weeks for the RC patients, but at 36 months, only 4 (3oo) of the R patients and 5 (4%0) of the RC patients were still alive.
There was evidence of recurrence of the primary cancer in 41 (35%) of the 117 R and 35 (32%) of the 110 RC patients who died. Distant metastases were more frequent in the R series, being reported in 99 (82o%) compared with 82 (71 %) of the RC patients (P<0-05 by log-rank test). The numbers of R patients alive and considered free of metastases were 10 (8%/) at 12 months, 3 (2o%) at 24 months and 3 (2 %) at 36 months; the corresponding figures for the RC patients being 30 (26%), 9 (8%), and 4 (3%).
SMALL-CELL CARCINOMA of the lung is usually treated by non-surgical methods. It is very sensitive to radiation and chemotherapy, and current management usually includes both (Hansen, 1980; Oldham & Greco, 1980) . Although survival has been improved, the best drug combinations and the best ways of using radiation therapy still remain to be defined.
The present study, to which patients were admitted between March 1975 and April 1977, was designed to compare radiotherapy alone (R) with radiotherapy followed by chemotherapy with cyclophosphamide, methotrexate and CCNU (RC). The main findings at 12 months (MRC Lung Cancer Working Party, 1979) were that in the RC series, there was a significantly increased survival (P=0-002 by log-rank test) distant metastases appeared later and less frequently, but adverse reactions were much more frequent and severe. In this report the results on all patients up to a minimum of 3 years are presented.
PLAN AND CONDUCT OF THE STUDY
The plan and conduct of the study were described in detail in the first report (MRC Lung Cancer Working Party, 1979) . The main points are summarized below%N.
Eligibility
Patients aged 70 years or less were eligible if they had a previously untreated histologically or cytologically proven small-cell carcinoma (Kreyberg et al., 1967) confined to the soft tissues of one hemithorax and the ipsilateral and contralateral scalene and lower cervical nodes, the cell type being confirmed by a single reference pathologist.
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Treatment
Patients were randomly allocated to treatment with either radiotherapy alone (R), or radiotherapy followed by 3-drug chemotherapy (RC).
Radiotherapy consisted of a megavoltage midline dosage of 30 Gy given in 15 fractions over 3 weeks, or a suitable biological equivalent. There was an interval of 3 weeks between the end of the radiotherapy and the first pulse of chemotherapy.
Chemotherapy consisted of 10 alternating 3-drug and 2-drug pulses at 3-week intervals, though it could be stopped before the completion of 10 pulses or prolonged beyond 10 pulses if the patient's progress warranted it. Cyclophosphamide (500 mg/M2) plus methotrexate (50 mg/M2) were given by i.v. injection on each occasion, 10 mg of inetoclopramide being included as an anti-emetic.
CCNU (50 mg/Mi2) was given orally on the first and alternating pulses thereafter. that is every 6 weeks for 5 pulses.
Reports and investigations
A report on each patient was completed pretreatment, at each attendance for treat-100 k. ment, monthly up to 18 months and then once every 3 months. These reports included information on the allocated therapy, additional palliative therapy, any adverse reactions encountered, and metastases.
RESULTS
A total of 253 patients were admitted from 16 centres in the U.K.; 17 were excluded (MRC Lung Cancer Working Party, 1979) , leaving 236 (121 R, 115 RC) for analysis.
Condition on admission
The details of the patients' condition on admission were given in the first report (MRC Lung Cancer Working Party, 1979 
Survival
The survival curves ( Fig.) show no difference up to the end of the first 3 months (well after the end of the course of radiotherapy). Thereafter there was increased survival in the RC series (P= 0 009, log-rank test). At 12 months 22 (818%) of the 121 R patients were alive (95%0 confidence limits 12-26oo), conmpared with 39 (34o%) of the 115 RC patients (limits 25-43%) (P=0009). However, at 36 months the corresponding figures were only 4 (3%0) and 5 (4%0) respectively.
The median survival was 25 weeks for the R patients (limits 22-34) and 43 weeks for the RC patients (limits 34-48).
Of the 4 R patients alive at 36 months, I died with metastases at 39 months, 1 is alive at 63 months, but with metastases, and 2 are alive, well and with no evidence of recurrence at 61 and 62 months, respectively. Of the 5 RC patients alive at 36 months, 2 died, 1 at 37 months with metastases, the other of cor pulmonale at 52 months with no evidence of cancer, 1 is alive at 53 months, but with metastases, and 2 are alive, well and with no evidence of recurrence at 38 and 50 months, respectively.
Proynostic factors
Age, weight, haemoglobin concentration, total white cell and platelet counts, clinical condition, grade of activity and respiratory assessment on admission, and sex were examined singly and in combination, using stratification of the log-rank test (Peto et at., 1977) for their relationship to survival. The only factors found to be significantly related were age (P = 0-03) and clinical condition (P = 0.03). A total of 12 patients were still receiving the prescribed chemotherapy at 12 months because their disease was still considered to be responding. Chemotherapy was eventually stopped after the 1 2-month dose for 1 of these 12 patients, at 1 4 months for 3, at 16 months for 2, and at 17, 18, 20, 23, 26 and 27 months for the remaining 6 respectively. Of the 1 2, 4 died while still receiving chemotherapy. Of the remaining 8, 3 were alive at 36 months having received 16, 23 and 27 months of chemotherapy, respectively; 1 of the 3 died at 37 months, the other 2 are alive at 50 and 53 months respectively, the first with no evidence of recurrence, the second with metastases.
Additional palliative treatment
Of the 117 R and 109 RC patients who completed the prescribed radiotherapy, 60 (51%0) of the R patients were given additional palliative therapy during the first 12 months, compared with 21 (19%o) of the RC patients. For the 60 R patients, this was chemotherapy alone for 17 (15%), radiotherapy alone for 25 (21 %), and radiotherapy and chemotherapy for the remaining 18 (15%). For all 21 of the RC patients it was radiotherapy alone.
During the second year a further 2 R patients had additional palliative treatment (one radiotherapy, the other radiotherapy and chemotherapy) as did 7 RC patients (1 radiotherapy, 6 radiotherapy and chemotherapy). During the third year, 2 other RC patients had palliative treatment (one radiotherapy, the other radiotherapy and chemotherapy). Thus, during the 36 months, a total of 62 (530o) of the R patients were given additional palliative treatment, compared with 30 (28%) of the RC patients (P = 00002).
Adverse reactions
The adverse reactions reported during the first 12 months were described in detail in the first report (MRC Lung Cancer Working Party, 1979 (Oldham & Greco, 1.980) . However, the great majority of patients still die of their disease, often very rapidly.
The results of this study are clearly not as good as the best reported (reviewed by Hansen, 1980 The use of radiotherapy in the management of local disease has been general practice until recently (reviewed by Bleehen, 1979; Salazar & Creech, 1980; Hansen, 1980) . The first MRC small-cell study (Fox & Scadding, 1973) demonstrated the superior results of radiotherapy alone over those of surgery alone, though this conclusion has subsequently been questioned (Levison, 1980) for a very selected series of patients whose disease is considered to be sufficiently localized for them to be treated with radiotherapy followed by surgery (usually pneumonectomy).
The radiation dosage to the local disease has varied very considerably in different series. Thus Salazar & Creech (1980) quote a mean total dosage of 45 Gy (range 42-55 Gy) in 446 patients treated by 10 different groups. The dosage selected for the present study was considerably lower, and was chosen in a deliberate attempt to keep radiation morbidity to a minimum, while permitting chemotherapy. The fact that about one third of all the patients treated in this study had clinical or radiographic evidence of persistence, extension or recurrence of the primary tumour, suggests that this radiation dosage was inadequate. However, there is little evidence in well conducted controlled studies, that higher radiation dosages do in fact improve local control or survival (reviewed by Bleehen, 1979, and . Also, in the present study, most of the patients with evidence of cancer at the primary site at death, had distant metastases; it is therefore doubtful whether a higher radiation dosage would have improved the results.
Radiotherapy has also been advocated as a method of controlling occult metastasis. This may involve whole-body or hemi-body irradiation (Dawes, 1980; Salazar et al., 1980) or, more usually, elective radiation to common metastatic sites, in particular the brain (Johnson et al., 1976; Livingston, 1979; Hansen, 1980) . While there is evidence that the incidence of CNS metastases may be reduced by such procedures, there is no evidence in randomized studies of an associated prolongation of survival (Hansen, 1980) .
The choice of the chemotherapy regimen has been discussed in the first report on this present study (MRC, 1979) and was based on the report by Hansen et al. (1976) of its efficacy. The results of the present study confirm its activity, in that its addition to the radiotherapy significantly improved survival. However, the inclusion of the drug CCNU was regarded unfavourably by many patients and their clinicians because of the associated side effects. The absence of any reduction in the incidence of CNS metastases has raised questions about its ability to control them.
Numerous other chemotherapy regimens have been reported, with varying results (Hansen, 1980; Oldham & Greco, 1980) . Of relevance to the present report are the results of a randomized trial by Hansen et al. (1980) using a very similar drug regimen and a not dissimilar total radiation dosage. Their staging investigations were more rigorous, and are therefore likely to have allowed the inclusion of a smaller proportion of patients with unrecognized "extensive" disease than in the present study, in which isotopic scans, marrow examination and peritoneoscopy were not mandatory. The median duration of survival reported by Hansen et al. (1980) was, however, very similar to that reported here, namely 310 days compared with 300 days (43 weeks), and the proportion of patients alive at 18 months was the same (13O% in both series). It is of interest that no improvement in survival was seen by the Danish group when they added irradiation of the brain, adrenals and upper retroperitoneal lymph nodes.
Better results, but in much smaller series of patients, have been reported, with a 2-year survival of 25% (Oldham & Greco, 1980) . If differences in patient selection are not the main or only reason for this difference, our failure to achieve such results may then relate to the choice of chemotherapy regimen. Evidence for this may be deduced from the study reported by Cohen et al. (1977) in which the 3-drug regimen (cyclophosphamide, methotrexate and CCNU) at similar dosages was compared with the same drugs given at approximately double dosages. Toxicity was considerably greater with the higher dosages, but so was the median survival. Other drugs with activity against smallcell lung cancer such as vincristine, Adriamycin, and the podophyllin derivatives, VP16-213 and VM26, are now being included in various combinations, and may produce better maintained survival.
In the present study, the sequence in which the two treatment modalities were combined was selected with the aim of controlling local disease with radiotherapy first before giving systemic treatment to occult disease. This sequence might be criticised as permitting the early development of metastases during the 6 weeks before chemotherapy. Data in favour of this concept have been reviewed (Bleehen, 1980; Salazar & Creech, 1980) but are inconclusive. This question of drugradiation sequence is being formally tested in the current (3rd) MRC small-cell study, and in a Swiss study (Alberto, personal communication) .
Finally, the necessity for radiotherapy in the primary management of the disease is now being questioned (reviewed by Hansen, 198C) . In 2 large randomized series of patients (total 259) median survival was not improved by the addition of radiotherapy to the selected drug regimens (Hansen et al., 1979; Fox et al., 1980) . It may well be that, with further improvements in chemotherapy, radiotherapy will have no place in the primary treatment. Alternatively, improved radiation therapy with radiosensitizers or particle therapy may, in the future, produce better control of local disease and enhance the systemic results of improved chemotherapy. Both these possibilities remain a matter for speculation. At present, the results of treating small-cell carcinoma of the lung remain poor, and considerably more effort with carefully documented randomized studies, after innovative pilot studies, is required.
